Cargando…
Giant cell tumor of bone revisited
Giant cell tumor (GCT) of bone is a locally aggressive benign neoplasm that is associated with a large biological spectrum ranging from latent benign to highly recurrent and occasionally metastatic malignant bone tumor. It accounts for 4–10% of all bone tumors and typically affects the meta-epiphyse...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
EDP Sciences
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598212/ https://www.ncbi.nlm.nih.gov/pubmed/28905737 http://dx.doi.org/10.1051/sicotj/2017041 |
_version_ | 1783263857428398080 |
---|---|
author | Mavrogenis, Andreas F. Igoumenou, Vasileios G. Megaloikonomos, Panayiotis D. Panagopoulos, Georgios N. Papagelopoulos, Panayiotis J. Soucacos, Panayotis N. |
author_facet | Mavrogenis, Andreas F. Igoumenou, Vasileios G. Megaloikonomos, Panayiotis D. Panagopoulos, Georgios N. Papagelopoulos, Panayiotis J. Soucacos, Panayotis N. |
author_sort | Mavrogenis, Andreas F. |
collection | PubMed |
description | Giant cell tumor (GCT) of bone is a locally aggressive benign neoplasm that is associated with a large biological spectrum ranging from latent benign to highly recurrent and occasionally metastatic malignant bone tumor. It accounts for 4–10% of all bone tumors and typically affects the meta-epiphyseal region of long bones of young adults. The most common site involved is the distal femur, followed by the distal radius, sacrum, and proximal humerus. Clinical symptoms are nonspecific and may include local pain, swelling, and limited range of motion of the adjacent joint. Radiographs and contrast-enhanced magnetic resonance imaging (MRI) are the imaging modalities of choice for diagnosis. Surgical treatment with curettage is the optimal treatment for local tumor control. A favorable clinical outcome is expected when the tumor is excised to tumor-free margins, however, for periarticular lesions this is usually accompanied with a suboptimal functional outcome. Local adjuvants have been used for improved curettage, in addition to systematic agents such as denosumab, bisphosphonates, or interferon alpha. This article aims to discuss the clinicopathological features, diagnosis, and treatments for GCT of bone. |
format | Online Article Text |
id | pubmed-5598212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | EDP Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-55982122017-09-21 Giant cell tumor of bone revisited Mavrogenis, Andreas F. Igoumenou, Vasileios G. Megaloikonomos, Panayiotis D. Panagopoulos, Georgios N. Papagelopoulos, Panayiotis J. Soucacos, Panayotis N. SICOT J Review Article Giant cell tumor (GCT) of bone is a locally aggressive benign neoplasm that is associated with a large biological spectrum ranging from latent benign to highly recurrent and occasionally metastatic malignant bone tumor. It accounts for 4–10% of all bone tumors and typically affects the meta-epiphyseal region of long bones of young adults. The most common site involved is the distal femur, followed by the distal radius, sacrum, and proximal humerus. Clinical symptoms are nonspecific and may include local pain, swelling, and limited range of motion of the adjacent joint. Radiographs and contrast-enhanced magnetic resonance imaging (MRI) are the imaging modalities of choice for diagnosis. Surgical treatment with curettage is the optimal treatment for local tumor control. A favorable clinical outcome is expected when the tumor is excised to tumor-free margins, however, for periarticular lesions this is usually accompanied with a suboptimal functional outcome. Local adjuvants have been used for improved curettage, in addition to systematic agents such as denosumab, bisphosphonates, or interferon alpha. This article aims to discuss the clinicopathological features, diagnosis, and treatments for GCT of bone. EDP Sciences 2017-09-14 /pmc/articles/PMC5598212/ /pubmed/28905737 http://dx.doi.org/10.1051/sicotj/2017041 Text en © The Authors, published by EDP Sciences, 2017 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Mavrogenis, Andreas F. Igoumenou, Vasileios G. Megaloikonomos, Panayiotis D. Panagopoulos, Georgios N. Papagelopoulos, Panayiotis J. Soucacos, Panayotis N. Giant cell tumor of bone revisited |
title | Giant cell tumor of bone revisited |
title_full | Giant cell tumor of bone revisited |
title_fullStr | Giant cell tumor of bone revisited |
title_full_unstemmed | Giant cell tumor of bone revisited |
title_short | Giant cell tumor of bone revisited |
title_sort | giant cell tumor of bone revisited |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598212/ https://www.ncbi.nlm.nih.gov/pubmed/28905737 http://dx.doi.org/10.1051/sicotj/2017041 |
work_keys_str_mv | AT mavrogenisandreasf giantcelltumorofbonerevisited AT igoumenouvasileiosg giantcelltumorofbonerevisited AT megaloikonomospanayiotisd giantcelltumorofbonerevisited AT panagopoulosgeorgiosn giantcelltumorofbonerevisited AT papagelopoulospanayiotisj giantcelltumorofbonerevisited AT soucacospanayotisn giantcelltumorofbonerevisited |